Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Clin Lung Cancer ; 22(3): e235-e292, 2021 05.
Article in English | MEDLINE | ID: mdl-32912754

ABSTRACT

BACKGROUND: The optimal treatment of stage I non-small-cell lung carcinoma is subject to debate. The aim of this study was to compare overall survival and oncologic outcomes of lobar resection (LR), sublobar resection (SR), and stereotactic body radiotherapy (SBRT). METHODS: A systematic review and meta-analysis of oncologic outcomes of propensity matched comparative and noncomparative cohort studies was performed. Outcomes of interest were overall survival and disease-free survival. The inverse variance method and the random-effects method for meta-analysis were utilized to assess the pooled estimates. RESULTS: A total of 100 studies with patients treated for clinical stage I non-small-cell lung carcinoma were included. Long-term overall and disease-free survival after LR was superior over SBRT in all comparisons, and for most comparisons, SR was superior to SBRT. Noncomparative studies showed superior long-term overall and disease-free survival for both LR and SR over SBRT. Although the papers were heterogeneous and of low quality, results remained essentially the same throughout a large number of stratifications and sensitivity analyses. CONCLUSION: Results of this systematic review and meta-analysis showed that LR has superior outcomes compared to SBRT for cI non-small-cell lung carcinoma. New trials are underway evaluating long-term results of SBRT in potentially operable patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/pathology , Disease-Free Survival , Humans , Lung Neoplasms/pathology , Neoplasm Staging , Pneumonectomy/methods , Radiosurgery/legislation & jurisprudence , Survival Rate , Treatment Outcome
2.
Cancer Radiother ; 24(2): 153-158, 2020 Apr.
Article in French | MEDLINE | ID: mdl-32089502

ABSTRACT

The radiobiological concepts described for conventional doses per fraction (1.8 to 2Gy) seem difficult to translate to high doses per fraction radiobiology. In fact, specific mechanisms are involved during high dose per fraction irradiation, involving vascular microenvironment damage and anti tumor immune response. The "5R's" of "classical" radiobiology (factors influencing the response of healthy or cancer cells to irradiation) seem to play a less important role in case of high doses per fraction. In addition, applicability of the linear quadratic model in this context is debated. It is therefore difficult to obtain reliable equivalent doses, hence the importance of including our patients in clinical trials, especially in case of concomitant systemic treatments. In addition to stereotactic radiotherapy, flash irradiations defined by a dose rate approximately 2000 times faster than "conventional" irradiation can also deliver high doses per fraction, with a much better tolerance for normal tissue without loss of anti tumor efficacy. Finally, availability of robust prospective data is a prerequisite to answer the question of short and long-term risk/benefit ratio of these different irradiation techniques.


Subject(s)
Dose Fractionation, Radiation , Neoplasms/radiotherapy , Radiobiology , Radiosurgery , Blood Vessels/radiation effects , Cell Cycle/radiation effects , Cell Death , Cell Proliferation , Cell Survival , Humans , Immunity, Cellular/radiation effects , Models, Theoretical , Oxygen Consumption , Radiation Tolerance , Radiobiology/legislation & jurisprudence , Radioimmunotherapy/methods , Radiosurgery/legislation & jurisprudence , Risk Assessment
3.
J Neurooncol ; 145(1): 159-165, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31485922

ABSTRACT

INTRODUCTION: Single-fraction stereotactic radiosurgery (SRS) is delivered predominantly via two modalities: Gamma Knife, and linear accelerator (LINAC). Implementation of the American Tax Payer Relief Act (ATRA) in 2013 represented the first time limitations specifically targeting SRS reimbursement were introduced into federal law. The subsequent impact of the ATRA on SRS utilization in the United States (US) has yet to be examined. METHODS: The National Cancer Database from 2010-2016 identified brain metastases patients from non-small cell lung cancer throughout the US having undergone SRS. Utilization between GKRS and LINAC was assessed before (2010-2012), during (2013-2014) and after (2015-2016) ATRA implementation. RESULTS: In 2013, there was a substantial decrease of LINAC SRS in favor of GKRS in non-academic centers. Over the 3-year span immediately preceding ATRA implementation, 39% of all eligible SRS cases received LINAC. There was a modest decrease in LINAC utilization over the 2 years immediately following ATRA implementation (35%), followed by an increase over the next two years (40%). SRS modality showed differences over the three time periods (unadjusted, p = 0.043), primarily in non-academic centers (unadjusted, p = 0.003). CONCLUSIONS: ATRA implementation in 2013 caused an initial spike in Gamma Knife SRS utilization, followed by a decline to rates similar to the years before implementation. These findings indicate that the ATRA provision mandating Medicare reduction of outpatient payment rates for Gamma Knife to be equivalent with those of LINAC SRS had a significant short-term impact on the radiosurgical treatment of metastatic brain disease throughout the US, serving as a reminder of the importance/impact of public policy on treatment modality utilization by physicians and hospitals.


Subject(s)
Brain Neoplasms/surgery , Carcinoma, Non-Small-Cell Lung/surgery , Health Policy/legislation & jurisprudence , Lung Neoplasms/surgery , Practice Patterns, Physicians'/statistics & numerical data , Radiosurgery/economics , Radiosurgery/legislation & jurisprudence , Adenocarcinoma of Lung/economics , Adenocarcinoma of Lung/pathology , Adenocarcinoma of Lung/surgery , Aged , American Recovery and Reinvestment Act , Brain Neoplasms/economics , Brain Neoplasms/secondary , Carcinoma, Large Cell/economics , Carcinoma, Large Cell/pathology , Carcinoma, Large Cell/surgery , Carcinoma, Non-Small-Cell Lung/economics , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/economics , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Female , Financing, Government , Follow-Up Studies , Humans , Lung Neoplasms/economics , Lung Neoplasms/pathology , Male , Middle Aged , Prognosis , United States
5.
Todo hosp ; (220): 570-576, oct. 2005. tab
Article in Spanish | IBECS | ID: ibc-59733

ABSTRACT

La radioterapia es una especialidad médica de gran complejidad técnica y que conlleva un cierto grado de riesgo en su aplicación. Por este motivo es objeto de una extensa y restrictiva regulación legal. En el presente artículo se analizan las consecuencias que tienen sobre ella las distintas disposiciones legales, haciendo especial hincapié en el Real Decreto de los Criterios de Calidad en Radioterapia (AU)


Because of the great technical complexity and the degree of risk in its application, Radiotherapy is a unique medical speciality with extensive and restrictive legal regulations. This work analyses the consequences of the different legal provisions, with special emphasis on the Royal Decree establishing the Quality Criteria in Radiotherapy (AU)


Subject(s)
Radiotherapy/ethics , Radiation Oncology/legislation & jurisprudence , Equipment Safety/standards , Safety/legislation & jurisprudence , Quality Control , Radiosurgery/legislation & jurisprudence , Radiation, Ionizing , Total Quality Management/legislation & jurisprudence , Medical Oncology/legislation & jurisprudence , Oncology Service, Hospital/legislation & jurisprudence
SELECTION OF CITATIONS
SEARCH DETAIL
...